


Management of Renal Cell Carcinoma (RCC) has continued to improve over the years, as the field of urology is constant evolving and has been a leader in the development surgical and medical strategies to deal with this very aggressive form of cancer. Urologists face a constant dilemma when dealing with RCC and struggle in deciding what is the best treatment option for each patient. This book describes the evolution of treatment for kidney cancer. During my residence, the only treatment option for RCC was radical nephrectomy but some of the urologic colleagues were started to perform partial nephrectomy. I believe that this book *Key Leaders' Opinion on Novel Progress in Treatment of Kidney Cancer* will become the state of the art reference for tailoring treatment according to the patient's disease. This book also presents recently developed therapeutics options once the disease is advanced.

This book will provide the urologist, oncologist, other clinicians, and more basic science researchers with the latest knowledge of surgical treatment, immunotherapy including immune checkpoints, stereotactic body radiation, minimally invasive treatment and latest developments of translational medicine. This book contains 77 chapters in 5 parts covering debates and difficulty in surgical treatment, precision medicine for individualized therapy, research and perspectives from fresh vision, basic research and translation medicine, molecular genetics, renal tumor immune dysfunction, and signal transduction. An acknowledged expert in that specialty wrote each of the articles, and the list of authors represents decades of experience in dealing with clinical management of RCC.

This book covers topics that over the years have been quite controversial, like lymph node dissection in RCC, nephrectomy in metastatic RCC with venous thrombus, surgical metastasectomy for RCC, acute kidney injury after partial nephrectomy, complex partial nephrectomy, use of anti-vascular and anti-endothelial growth factor targeted agents before cytoreductive surgery, active surveillance and the role of immunotherapy among many other topics. We are dealing with a very difficult disease hoping that this book helps to improve the current knowledge about RCC, reflecting a multidisciplinary approach concerning managing patients with RCC.

This book has reunited the best experts from all over the globe in the field of RCC. We thank their experience, efforts and dedication in making this book one of the most comprehensive when dealing with RCC and covering a broad spectrum of topics. The main message of this book is to help the physician in making the right decision(s) for the patient management with RCC.

I am very proud to say that all the authors have contributed pivotal research to bring to the urologic oncology field what is new on the horizon.



Gaetano Ciancio, MD, MBA, FACS
Department of Surgery and Urology,
Miami Transplant Institute,
University of Miami Miller School of Medicine,
Jackson Memorial Hospital Miami,
Miami, FL, USA